- Home
- BRT vs PRQR Comparison
BRT vs PRQR Comparison
Compare BRT & PRQR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- PRQR
- Stock Information
- Founded
- BRT 1972
- PRQR 2012
- Country
- BRT United States
- PRQR Netherlands
- Employees
- BRT N/A
- PRQR N/A
- Industry
- BRT Real Estate Investment Trusts
- PRQR Biotechnology: Pharmaceutical Preparations
- Sector
- BRT Real Estate
- PRQR Health Care
- Exchange
- BRT Nasdaq
- PRQR Nasdaq
- Market Cap
- BRT 330.2M
- PRQR 309.5M
- IPO Year
- BRT N/A
- PRQR 2014
- Fundamental
- Price
- BRT $17.58
- PRQR $2.19
- Analyst Decision
- BRT Strong Buy
- PRQR Strong Buy
- Analyst Count
- BRT 3
- PRQR 5
- Target Price
- BRT $22.17
- PRQR $7.60
- AVG Volume (30 Days)
- BRT 26.8K
- PRQR 363.5K
- Earning Date
- BRT 03-11-2025
- PRQR 03-12-2025
- Dividend Yield
- BRT 5.67%
- PRQR N/A
- EPS Growth
- BRT N/A
- PRQR N/A
- EPS
- BRT N/A
- PRQR N/A
- Revenue
- BRT $96,743,000.00
- PRQR $20,506,357.00
- Revenue This Year
- BRT N/A
- PRQR $210.30
- Revenue Next Year
- BRT $5.73
- PRQR $39.89
- P/E Ratio
- BRT N/A
- PRQR N/A
- Revenue Growth
- BRT 1.95
- PRQR 306.68
- 52 Week Low
- BRT $15.21
- PRQR $1.61
- 52 Week High
- BRT $20.22
- PRQR $4.62
- Technical
- Relative Strength Index (RSI)
- BRT 50.76
- PRQR 42.45
- Support Level
- BRT $16.84
- PRQR $1.95
- Resistance Level
- BRT $17.65
- PRQR $2.46
- Average True Range (ATR)
- BRT 0.43
- PRQR 0.16
- MACD
- BRT 0.07
- PRQR 0.03
- Stochastic Oscillator
- BRT 74.00
- PRQR 53.31
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.